 |
|
Multicenter Double-blind Comparison of Sertraline and Desipramine for Concurrent Obsessive-Compulsive and Major Depressive Disorders
Rudolf Hoehn-Saric, MD;
Philip Ninan, MD;
Donald W. Black, MD;
Stephen Stahl, MD;
John H. Greist, MD;
Bruce Lydiard, MD;
Susan McElroy, MD;
John Zajecka, MD;
Douglass Chapman, MS;
Cathryn Clary, MD;
Wilma Harrison, MD
Arch Gen Psychiatry. 2000;57:76-82.
Background Serotonin reuptake inhibitors (SRIs) have demonstrated consistent efficacy in the treatment of obsessive-compulsive disorder (OCD), while agents that are primarily norepinephrine reuptake inhibitors have not. Comparable efficacy has been demonstrated for SRI and non-SRI antidepressants in uncomplicated major depressive disorder (MDD). This multicenter trial is the first comparison of an SRI (sertraline) and a non-SRI antidepressant (desipramine) in the treatment of OCD with concurrent MDD.
Methods One hundred sixty-six patients diagnosed using structured clinical interviews and recruited from 16 treatment sites were randomly assigned to double-blind treatment with either sertraline (up to 200 mg/d) or desipramine (up to 300 mg/d) over 12 weeks. Measures of severity of OCD and MDD symptoms, as well as adverse effects of the medications, were monitored over the course of the treatment period.
Results Patients assigned to sertraline responded significantly better at end point on measures of OCD and MDD symptoms compared with patients assigned to desipramine. Sertraline was also associated with a significantly greater number of patients who achieved a "robust" improvement in OCD symptoms ( 40% reduction) compared with desipramine. More patients receiving desipramine than sertraline discontinued treatment because of adverse events.
Conclusions The SRI sertraline was more effective in reducing MDD and OCD symptoms than the primarily norepinephrine reuptake inhibitor desipramine for patients with concurrent OCD and MDD.
From the Departments of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, Md (Dr Hoenh-Saric), Emory University, Atlanta, Ga (Dr Ninan), and Medical University of South Carolina, Charleston (Dr Lydiard); Departments of Psychiatry, University of Iowa, Iowa City (Dr Black), University of California at San Diego (Dr Stahl), University of Cincinnati College of Medicine, Cincinnati, Ohio (Dr McElroy), and Rush-Presbyterian/St Luke's Medical Center, Chicago, Ill (Dr Zajecka); Madison Institute of Medicine, Madison, Wis (Dr Griest); and Pfizer Inc, New York, NY (Mr Chapman and Drs Clary and Harrison).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Risk assessment and management in obsessive-compulsive disorder
Veale et al.
Adv. Psychiatr. Treat. 2009;15:332-343.
ABSTRACT
| FULL TEXT
STAR*D: a summary and UK perspective
Deakin and O'Loughlin
J Psychopharmacol 2009;23:605-612.
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines
Anderson et al.
J Psychopharmacol 2008;22:343-396.
ABSTRACT
Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology
Baldwin et al.
J Psychopharmacol 2005;19:567-596.
ABSTRACT
Differential Cerebral Metabolic Changes With Paroxetine Treatment of Obsessive-Compulsive Disorder vs Major Depression
Saxena et al.
Arch Gen Psychiatry 2002;59:250-261.
ABSTRACT
| FULL TEXT
Superiority of an SRI in Depression Associated with OCD
JWatch Psychiatry 2000;2000:5-5.
FULL TEXT
|
